Gen-Probe to File PMA for PCA3 Assay; Possible Alternative to PSA

The company has begun a clinical trial for its Progensa PCA3 assay, enrolling 500 men who have had a negative prostate biopsy. The study is slated to complete in less than a year, at which point the company expects to submit its PMA to the FDA.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.